← Issue №19/ week of Nov 8, 2026/IBD

Microbial and antimicrobial resistance signatures differentiate healthy and inflamed ileal pouches in patients with ulcerative colitis.

From GI Signals issue №19: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD prospective cohort · n=190 · Nov 7, 2026 · J of Crohn's and Colitis · IF 8.3

Microbial and antimicrobial resistance signatures differentiate healthy and inflamed ileal pouches in patients with ulcerative colitis.

Basic sciencemicrobiomepouchitisbasic science
Clinical takeawayNo clinical action yet: a mechanistic finding on microbial resistance patterns in pouchitis. Consider integrating plasmid analysis into metagenome-based approaches for personalized antibiotic treatment in future research.
What it foundE. coli in SickPouch had significantly higher ciprofloxacin resistance mutations (gyrA and parC genes) compared to HealthyPouch (P < .05) and NormalGut (P < .05).
ContextChallenges the assumption that FMT from a healthy colon microbiome is optimal for pouchitis, suggesting HealthyPouch microbiota may be more appropriate. Opens a question on antibiotic resistance monitoring in pouchitis.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Dall SM … Albertsen M · Journal of Crohn's and Colitis · IF 8.3 · PubMed ↗Permalink
← Read the whole of issue №19 Every paper GI Signals surfaces gets a page like this one. All issues